NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.01.25	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Businesswire)
03.01.25	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Businesswire)
05.12.24	Novocure gibt positive Ergebnisse der Phase-3-Studie PANOVA-3 zur Tumor Treating Fields (TTFields)-Therapie bei Bauchspeicheldrüsenkrebs bekannt (Businesswire)
02.12.24	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Businesswire)
27.11.24	Novocure to Participate in Upcoming Investor Conferences (Businesswire)
21.11.24	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Businesswire)
21.11.24	FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma (Businesswire)
31.10.24	Novocure meldet Finanzergebnisse des dritten Quartals 2024 (Businesswire)
31.10.24	Novocure ernennt Christoph Brackmann zum Finanzvorstand (Businesswire)
30.10.24	Novocure Appoints Christoph Brackmann as Chief Financial Officer (Businesswire)
30.10.24	Novocure Reports Third Quarter 2024 Financial Results (Businesswire)
22.10.24	FDA genehmigt Optune Lua® von Novocure zur Behandlung des metastasierenden nicht-kleinzelligen Lungenkarzinoms (Businesswire)
15.10.24	FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer (Businesswire)
01.10.24	Novocure to Report Third Quarter 2024 Financial Results (Businesswire)
09.09.24	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Businesswire)
03.09.24	Novocure Announces Planned CEO Transition (Businesswire)
28.08.24	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Businesswire)
14.08.24	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Businesswire)
25.07.24	Novocure Reports Second Quarter 2024 Financial Results (Businesswire)
01.07.24	Novocure to Report Second Quarter 2024 Financial Results (Businesswire)
03.06.24	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Businesswire)
24.05.24	TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland (Businesswire)
02.05.24	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Businesswire)
02.05.24	Novocure Reports First Quarter 2024 Financial Results (Businesswire)
01.04.24	Novocure to Report First Quarter 2024 Financial Results (Businesswire)
11.03.24	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Businesswire)
22.02.24	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Businesswire)
18.01.24	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Businesswire)
09.01.24	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Businesswire)
08.01.24	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Businesswire)
04.01.24	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Businesswire)
27.12.23	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Businesswire)
28.11.23	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Businesswire)
21.11.23	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Businesswire)
10.11.23	Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting (Businesswire)
26.10.23	Novocure Reports Third Quarter 2023 Financial Results (Businesswire)
16.10.23	Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 (Businesswire)
12.10.23	Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program (Businesswire)
29.09.23	Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting (Businesswire)
08.09.23	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Businesswire)
30.08.23	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Businesswire)
28.08.23	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Businesswire)
25.08.23	Novocure to Participate in Upcoming Investor Conferences (Businesswire)
27.07.23	Novocure Reports Second Quarter 2023 Financial Results (Businesswire)
21.07.23	Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer (Businesswire)
03.07.23	Novocure to Report Second Quarter 2023 Financial Results (Businesswire)
01.06.23	Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education (Businesswire)
04.05.23	Novocure Reports First Quarter 2023 Financial Results (Businesswire)
26.04.23	Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Businesswire)
14.04.23	Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	56.58	1.58 %	K V
Sonova Hldg	244.90	1.53 %	K V
Alcon	63.84	1.27 %	K V
Logitech Intl	86.34	0.91 %	K V
Sika	184.90	-0.40 %	K V
Swiss Re	141.05	-0.42 %	K V
Kuehne+Nagel Int	164.05	-0.49 %	K V
Lonza Grp	560.40	-1.41 %	K V
Givaudan	3’456.00	-2.07 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

NovoCure Aktie VALOR 29570025 / ISIN JE00BYSS4X48

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten